Last reviewed · How we verify
NCT07315204
Viability Assessment Using FMN Measured in Perfusate and Bile During Normothermic Machine Perfusion
trial in Liver Transplant Disorder in 850 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | The Cleveland Clinic |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 850 |
| Start date | 29 December 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across United States |
Conditions studied
- Liver Transplant Disorder — all drugs for Liver Transplant Disorder →
Sponsor
The Cleveland Clinic
Who can join
18 and older, any sex, with Liver Transplant Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Discarded perfusate samples will be collected from donors after circulatory death (DCD) or donors after brain death (DBD) organs during the machine perfusion period prior to transplantation by the study team. FMN will be measured as is standard of care for all machine perfusion liver transplant cases at Cleveland Clinic. Participating centers will be provided with sample collection and shipping instructions to ensure sample preservation in accordance with IATA guidelines. Samples from outside sites will not be stored for future research and will be discarded once analysis is completed. After the collection of the samples from machine perfusion, the transplant procedure will continue according to standard process.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07315204
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Transplant Disorder
Currently open trials in the same condition.
- NCT06455280 — A Study of SIPLIZUMAB in AILD and LT Patients · Phase 1 · recruiting
- NCT06577480 — Validity and Reliability of the Turkish Version of the Post-Liver Transplant Quality of Life Questionnaire · active not recruiting
- NCT06563570 — The Effect of Teleyoga in Liver Transplant Patients · NA · active not recruiting
- NCT05537948 — Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients · Phase 4 · active not recruiting
- NCT05761483 — Endoscopic Management of Non-anastomotic Biliary Strictures Following Liver Transplantation. · recruiting
Other The Cleveland Clinic trials
Trials by the same sponsor.
- NCT07218198 — Clinical Decision Support Tool for the Treatment of Uncontrolled Hypertension · NA · not yet recruiting
- NCT07442747 — Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS · NA · not yet recruiting
- NCT07471464 — Centered Surgery - Preoperative Counseling and Patient Satisfaction · recruiting
- NCT07073963 — Virtual Patient Groups for Sarcoidosis Associated Fatigue · NA · recruiting
- NCT07363343 — Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07315204 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Cleveland Clinic
- Last refreshed: 7 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07315204.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing